Current and historical daily PE Ratio for Cleo Diagnostics Ltd (
) from 2023 to Nov 10 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Cleo Diagnostics stock (ASX:COV) PE ratio as of Nov 10 2024 is 0.
More Details
Cleo Diagnostics Ltd (ASX:COV) PE Ratio (TTM) Chart
Cleo Diagnostics Ltd (ASX:COV) PE Ratio (TTM) Historical Data
View and export this data going back to 2023. Start your Free Trial
Total 318
- 1
- 2
- 3
- 4
| Cleo Diagnostics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-11-10 | At Loss | 2024-09-09 | At Loss |
| 2024-11-08 | At Loss | 2024-09-06 | At Loss |
| 2024-11-07 | At Loss | 2024-09-05 | At Loss |
| 2024-11-06 | At Loss | 2024-09-04 | At Loss |
| 2024-11-05 | At Loss | 2024-09-03 | At Loss |
| 2024-11-04 | At Loss | 2024-09-02 | At Loss |
| 2024-11-01 | At Loss | 2024-08-30 | At Loss |
| 2024-10-31 | At Loss | 2024-08-29 | At Loss |
| 2024-10-30 | At Loss | 2024-08-28 | At Loss |
| 2024-10-29 | At Loss | 2024-08-27 | At Loss |
| 2024-10-28 | At Loss | 2024-08-26 | At Loss |
| 2024-10-25 | At Loss | 2024-08-23 | At Loss |
| 2024-10-24 | At Loss | 2024-08-22 | At Loss |
| 2024-10-23 | At Loss | 2024-08-21 | At Loss |
| 2024-10-22 | At Loss | 2024-08-20 | At Loss |
| 2024-10-21 | At Loss | 2024-08-19 | At Loss |
| 2024-10-18 | At Loss | 2024-08-16 | At Loss |
| 2024-10-17 | At Loss | 2024-08-15 | At Loss |
| 2024-10-16 | At Loss | 2024-08-14 | At Loss |
| 2024-10-15 | At Loss | 2024-08-13 | At Loss |
| 2024-10-14 | At Loss | 2024-08-12 | At Loss |
| 2024-10-11 | At Loss | 2024-08-09 | At Loss |
| 2024-10-10 | At Loss | 2024-08-08 | At Loss |
| 2024-10-09 | At Loss | 2024-08-07 | At Loss |
| 2024-10-08 | At Loss | 2024-08-06 | At Loss |
| 2024-10-07 | At Loss | 2024-08-05 | At Loss |
| 2024-10-04 | At Loss | 2024-08-02 | At Loss |
| 2024-10-03 | At Loss | 2024-08-01 | At Loss |
| 2024-10-02 | At Loss | 2024-07-31 | At Loss |
| 2024-10-01 | At Loss | 2024-07-30 | At Loss |
| 2024-09-30 | At Loss | 2024-07-29 | At Loss |
| 2024-09-27 | At Loss | 2024-07-26 | At Loss |
| 2024-09-26 | At Loss | 2024-07-25 | At Loss |
| 2024-09-25 | At Loss | 2024-07-24 | At Loss |
| 2024-09-24 | At Loss | 2024-07-23 | At Loss |
| 2024-09-23 | At Loss | 2024-07-22 | At Loss |
| 2024-09-20 | At Loss | 2024-07-19 | At Loss |
| 2024-09-19 | At Loss | 2024-07-18 | At Loss |
| 2024-09-18 | At Loss | 2024-07-17 | At Loss |
| 2024-09-17 | At Loss | 2024-07-16 | At Loss |
| 2024-09-16 | At Loss | 2024-07-15 | At Loss |
| 2024-09-13 | At Loss | 2024-07-12 | At Loss |
| 2024-09-12 | At Loss | 2024-07-11 | At Loss |
| 2024-09-11 | At Loss | 2024-07-10 | At Loss |
| 2024-09-10 | At Loss | 2024-07-09 | At Loss |
Cleo Diagnostics Ltd (ASX:COV) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Cleo Diagnostics Ltd
ISIN : AU0000288045
Description
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers